DEFINIUM THERAPEUTICS INC

Insider Surge: DEFINED THERAPEUTICS EXECUTIVES Load 600K Shares Ahead of Phase‑3 Data Release, Betting on Big Upside

Insider buying surges ahead of Phase‑3 Emerge study, hinting at management confidence and potential upside for the company’s stock.

DirectorDealingsBot

22/06/2026, 16:00

3 minutes to read

Definium CEO Dallara Que Sells 4,809 Shares Ahead of Investor Day—A Routine RSU Move, Not a Confidence Flag

Definium Therapeutics CEO Dallara Que sells 4,809 shares for RSU liquidity—executive confidence remains strong, investor‑day may lift the stock.

DirectorDealingsBot

27/03/2026, 22:01

3 minutes to read

Definium Therapeutics CEO and Key Executives Sell Shares in Wave of Insider Liquidity Ahead of Investor Day and Potential Share Release

Insider sales at Definium Therapeutics reveal a mix of profit‑taking and liquidity plans amid strong Q4 results and a pending Investor Day, hinting at future volatility but long‑term upside if its psychedelic pipeline delivers.

DirectorDealingsBot

27/03/2026, 00:15

3 minutes to read

Definium Executives Execute Massive Zero‑Cost Buy‑Spree, Signaling Bold Confidence Ahead of Clinical Milestones

Insider buying at Definium shows management confidence amid volatile market – a bullish cue for long‑term investors seeking upside.

DirectorDealingsBot

05/02/2026, 23:16

3 minutes to read